Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 9/20 | 0.58 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212771 | 0.94 | FGFR3 (0.53) | FGFR3PDE1BFGFR1IDH1FGFR4 | |
| SCHEMBL1126124 | 0.82 | FGFR3 (0.72) | FGFR3FGFR1FGFR4 | |
| SCHEMBL3315714 | 0.81 | HPGDS (0.40) | FGFR3FGFR4SRC | |
| SCHEMBL1126188 | 0.80 | FGFR3 (0.38) | FGFR3FGFR1FGFR4CRHR1SRC | |
| SCHEMBL1126531 | 0.79 | FGFR3 (0.40) | FGFR3FGFR4CRHR1SRC | |
| SCHEMBL13626907 | 0.79 | FGFR3 (0.40) | FGFR3FGFR4CRHR1SRC | |
| SCHEMBL14212778 | 0.77 | FGFR3 (0.65) | FGFR3FGFR1FGFR4 | |
| SCHEMBL1126157 | 0.76 | FGFR3 (0.38) | FGFR3FGFR4 | |
| SCHEMBL1126172 | 0.76 | FGFR3 (0.38) | FGFR3FGFR1FGFR4CRHR1 | |
| SCHEMBL1126250 | 0.76 | FGFR3 (0.37) | FGFR3FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-8815901-B2 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8815901-B2 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2282995-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885PDE1B 1115/4885FGFR1 750/4885 |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FGFR3 763/4885PDE1B 1006/4885FGFR1 356/4885 |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FGFR3 763/4885PDE1B 1006/4885FGFR1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.